A Phase 3, multicenter, randomized, double-blind, 48-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized high-risk participants with COVID-19

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Scope

National

Locations

Outpatient CTRC

Principal Investigator
Photograph of Thomas Campbell,  MD

Thomas Campbell, MD

Study ID

Protocol Number: 22-0587

More information available at ClinicalTrials.gov: NCT05305547

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers